Ulthera vs Sofwave Research: What the Comparative Data Says

The most common question a friend asks me before booking a Gangnam appointment is some version of: which one has the better data. It is a fair question, and the honest answer is more complicated than either device's marketing department wants it to be. Between 2018 and 2025, the published peer-reviewed literature comparing Ultherapy (Merz, MFU) and Sofwave (Sofwave Medical, SUPERB) has grown from a handful of small open-label studies to a more substantial body of work — but the methodology choices, sponsor disclosures, and primary endpoint definitions vary widely. This article is a reporter's read of what that literature actually supports and where it falls silent. I have no financial relationship with either manufacturer. I have a personal preference for Ultherapy as a patient. I have tried to keep that preference out of the way of the data here, and to flag it when I cannot.

The shape of the comparative literature, as of 2026

The Ultherapy versus Sofwave comparative literature is built primarily on single-arm device studies, with a small number of split-face or matched-pair comparisons published since 2022. PubMed indexes several dozen Ultherapy outcome studies dating back to the device's FDA clearance window in 2009-2012, and a smaller but growing set of Sofwave outcome studies dating back to its 2019 U.S. clearance. Direct head-to-head studies — where the same patient or matched-cohort patients receive both devices on different facial halves or in randomized assignment — remain limited as of early 2026, and the ones that exist tend to carry methodology caveats worth reading carefully.

A 2023 review article in the Journal of Cosmetic Dermatology summarized the available comparative data and noted that most published comparisons rely on physician-rated improvement scales rather than blinded patient self-reports, and that follow-up windows vary substantially between studies — some at three months, some at six, a few at twelve. That methodological inconsistency is the single most important caveat for patients trying to compare results across studies. A device that performs strongly at three months may show a different profile at twelve, and a study that ends its primary endpoint window early may overstate or understate the durability of the effect.

A second structural caveat: the open-label nature of most aesthetic device studies makes blinding difficult. Both physicians and patients can usually identify which device delivered the treatment based on the chair experience and recovery profile, which can introduce bias into self-reported outcomes. Studies suggest that physician-rated improvement scales, when administered by independent and blinded raters, produce more conservative estimates of effect size than studies relying on the treating physician's own assessment. The literature reflects both approaches, and a careful reader should note which approach a specific study used.

Sponsor disclosure and the conflict-of-interest picture

Sponsor disclosure is the single most important variable a patient should look at when reading aesthetic device studies, and it is also the variable that varies most across the Ultherapy and Sofwave literature. Several of the foundational Ultherapy outcome studies from the 2010s were funded by Ulthera Inc. (the original manufacturer, later acquired by Merz Aesthetics) and list Ulthera-affiliated investigators or carry sponsor disclosure language. Several of the foundational Sofwave studies are similarly Sofwave Medical-funded or list Sofwave-affiliated investigators. This is not a disqualifier — industry-funded research is the norm in aesthetic medicine, and the FDA and MFDS clearance pathways often require sponsor-funded clinical work. But it changes how the data should be weighted, particularly when a sponsor-funded study's results align unusually closely with that sponsor's marketing claims.

The specific conflict-of-interest pattern worth flagging in the comparative literature is when a head-to-head study is funded by one of the two manufacturers being compared. A 2021 paper comparing SUPERB and a competitor MFU technology, for example, listed Sofwave Medical as the funding source and Sofwave-affiliated investigators on the author list. The paper's results favored SUPERB on the primary endpoint, which is consistent with how a manufacturer-funded comparison typically reads. A different 2022 paper using a similar comparison design but funded independently or by a non-manufacturer source produced more equivocal results. Both papers are real. Both are imperfect. The honest synthesis is to read them together rather than to weight either as definitive.

A reporter-flavored note on this: the absence of a clear sponsor disclosure in a published study is itself information. Reputable journals require disclosure, and most published aesthetic device studies include the relevant statement at the article foot. Studies that omit, obscure, or bury this information warrant a more skeptical read. The same applies to studies that disclose a financial relationship in vague terms — for example, listing an author as having received "educational support" from a manufacturer without specifying the scope or recency of that support.

Sample size, primary endpoints, and the durability question

Sample sizes in the Ultherapy versus Sofwave comparative literature run from the low double digits to a few studies in the hundred-plus range, with the median sitting around forty to sixty patients per arm. That is a small sample-size profile by general medical-research standards, and it has methodological consequences. Smaller studies are more sensitive to outlier responses, less robust to subgroup analysis, and more likely to produce statistically significant findings that fail to replicate. A patient reading a forty-patient comparative study should treat the conclusions as suggestive rather than definitive, and should look for replication across multiple studies before treating any specific finding as established.

Primary endpoint definitions vary across the literature. Some Ultherapy studies use a physician-rated lifting improvement scale at six months as the primary endpoint. Some Sofwave studies use a similar physician-rated scale but at three or four months. A few studies in both sets use blinded photographic assessment by independent raters, which is methodologically stronger. The patient-relevant question is whether a study that demonstrates an effect at three months also demonstrates persistence at twelve months, and that follow-up duration question is where the comparative literature is thinnest. Studies suggest both technologies produce visible effects at three to six months in most patients; the twelve-to-eighteen-month durability question is supported by a smaller body of work, and the head-to-head durability comparison is supported by an even smaller body.

The practical synthesis for patients: if a brochure cites a specific percentage improvement at a specific timepoint, look for the underlying study, the sample size, the primary endpoint definition, and the follow-up duration. If those four pieces of information are not readily available, the brochure claim is doing more work than the data supports. May help is the right framing for any specific durability claim — particularly any claim that one device's effect persists meaningfully longer than the other's, since the comparative durability data is genuinely thin and the available studies do not converge on a clear winner on that specific question.

What the literature actually supports for patient decisions

Reading the comparative literature carefully, here is what I would describe as well-supported and what I would describe as more speculative.

Well-supported: both Ultherapy and Sofwave produce visible improvement in skin laxity in most patients in the first three to six months after treatment. Both have established safety profiles in trained hands across the published literature. Both target ultrasound energy at distinct anatomical depths — Ultherapy at three depths including the SMAS at 4.5mm, Sofwave at approximately 1.5mm in the mid-dermis — and that depth difference is reflected in the kinds of indications each device is most commonly cleared for. Adverse events for both technologies are predominantly transient and mild when device protocols are respected and the operator is appropriately trained.

More speculative: claims that one device produces meaningfully better results than the other across all patients, claims that one device's results last meaningfully longer than the other's, and claims that one device is significantly more comfortable or significantly safer than the other in head-to-head comparison. The data supporting these comparative claims is thinner than marketing copy implies, and where comparative claims do appear, they often come from sponsor-funded studies whose results align with the sponsor's commercial interest. A patient making a device choice on the basis of a single comparative claim should look at the funding source and the methodology before treating that claim as decision-grade evidence.

The most useful patient-facing reading of the comparative literature, in my view, is that the device choice question is better framed as an indication-match question than as a head-to-head superiority question. Studies suggest the right device depends on whether a patient's primary concern is structural laxity (where Ultherapy's depth profile reaches the SMAS) or dermal-level texture and tone (where Sofwave's mid-dermal coverage is engineered). The comparative literature is consistent with that framing and inconsistent with a winner-take-all framing.

How to read a comparative study before booking

If you are the kind of patient who actually pulls the underlying papers before booking — and some of you are, in my experience — here is the checklist I have built for myself after several rounds of reading these studies. None of this replaces medical advice, and a provider's read of the literature in the context of your specific anatomy will almost always be more useful than your own.

First, look at the funding source and disclosure. A sponsor-funded study comparing the sponsor's device to a competitor warrants a more skeptical read on the primary endpoint than an independently funded study. Second, look at the sample size and the primary endpoint definition. A small study using a physician-rated scale administered by the treating physician is methodologically weaker than a larger study using blinded independent raters. Third, look at the follow-up duration. A study that reports its primary endpoint at three months tells you less about durability than a study that follows patients through twelve. Fourth, look at the patient population and inclusion criteria. A study limited to patients with mild laxity tells you less about moderate or severe presentations than a study with a broader patient profile. Fifth, look at whether the findings have been replicated in other studies, and ideally in studies funded by independent sources.

A last point on reading the literature responsibly: published peer-reviewed work is the most rigorous part of the conversation, but the device-marketing ecosystem also relies heavily on conference posters, manufacturer-sponsored white papers, and case reports that have not gone through equivalent peer review. These materials can be informative, but they should not be treated as equivalent to peer-reviewed studies, and they should be flagged when a brochure or sales presentation cites them as supporting evidence. The honest reader notes the source type and weights it accordingly.

What this reporter takes from the comparative data

If a friend asked me what to take from the Ultherapy versus Sofwave comparative literature in 2026, here is the version I would give her over coffee, with the journalistic caveats kept in. The comparative data supports both devices as effective for their respective primary indications, with safety profiles that are well-characterized and adverse event rates that are low when protocols are followed by trained operators. The data does not strongly support a winner-take-all framing in either direction, and most of the head-to-head claims I see in marketing copy outrun what the underlying studies actually demonstrate. The data is most useful for narrowing the indication-match question — which device is the better depth fit for a specific concern — and least useful for adjudicating absolute superiority claims.

A second observation, less from the data and more from spending time reading it: the comparative literature on aesthetic ultrasound devices is improving in quality over time. Sample sizes are growing, blinding methodology is improving in newer studies, and follow-up durations are extending. The literature in 2026 is meaningfully better than the literature in 2018, and the literature in 2030 will almost certainly be better than the literature in 2026. A patient making a device choice today is not making a permanent decision on the basis of a permanently fixed evidence base. The protocols, the operator training, and the device generations are all moving forward, and a patient's relationship with a single device is rarely a one-shot commitment.

The honest synthesis I would put at the bottom of this report: pick the device that matches your indication, the operator who has logged meaningful case volume on it, and the clinic whose protocol you trust. Read the literature as input, not as verdict. The data supports both devices as legitimate options and does not support a clean comparative ranking. Anyone claiming otherwise — in a brochure, in a sales presentation, or on a social platform — is doing more interpretive work than the underlying studies authorize.

Frequently asked questions

Are there any large randomized head-to-head trials between Ultherapy and Sofwave?

As of early 2026, large randomized head-to-head trials remain limited. Most published comparative work is built on single-arm device studies or smaller split-face or matched-pair designs, with sample sizes typically running from the low double digits to a few studies in the hundred-plus range. Studies suggest both devices are effective for their respective primary indications; the head-to-head comparative evidence base is thinner than marketing copy implies, and patients should weight individual comparative claims accordingly.

How important is sponsor disclosure when reading these studies?

Sponsor disclosure is one of the most important variables to weight when reading aesthetic device studies. A sponsor-funded comparison whose results align closely with the sponsor's marketing claims warrants a more skeptical read than an independently funded study with similar findings. Sponsor funding is the norm in aesthetic medicine and is not a disqualifier, but it changes how the data should be interpreted, particularly for head-to-head claims of superiority.

What is a primary endpoint and why does it matter?

The primary endpoint is the main outcome measure a study is designed to test. In aesthetic device studies, this is often a physician-rated improvement scale at a specific timepoint, such as three or six months post-treatment. Endpoint definitions vary across the comparative literature, which makes cross-study comparisons difficult. A study that demonstrates an effect at three months may show a different profile at twelve, and the durability question is where the comparative literature is thinnest.

Is one device more comfortable than the other based on the published data?

Patient-reported comfort varies across studies, and head-to-head comfort comparisons are limited and methodologically uneven. Sofwave's integrated surface cooling is often cited as contributing to a milder chair experience versus Ultherapy at the deepest passes, but comfort is also influenced strongly by operator pacing, numbing protocols, and patient-specific tolerance. The published data supports both devices as generally well-tolerated; the comparative comfort claim is supported by less rigorous evidence than marketing copy implies.

What does open-label mean in these studies?

Open-label means both the patient and the treating physician know which treatment was administered, as opposed to a blinded study where one or both parties do not. Most aesthetic device studies are open-label by necessity — the chair experience and recovery profile usually identify the device — which can introduce bias into self-reported outcomes. Studies using blinded independent raters of pre- and post-treatment photographs produce more conservative estimates of effect size and are methodologically stronger than open-label studies relying on the treating physician's own assessment.

Where can I read the original comparative studies myself?

PubMed, the U.S. National Library of Medicine database, indexes most peer-reviewed dermatology and aesthetic medicine journals and is publicly searchable. Search terms including the specific device names, ultrasound modality, and lifting indication will surface the relevant literature. The Journal of Cosmetic Dermatology, Dermatologic Surgery, and Lasers in Surgery and Medicine are common publication venues for this category of work. Reading the abstract is rarely sufficient — the methods, sample size, and disclosure sections are where the meaningful caveats usually live.